Valeant Pharma receives additional notice of default on delayed 1Q’16 filing

Troubled pharma firm Valeant Pharmaceuticals International, Inc. received a notice of default from the trustee under two of its senior note indentures on 2 June 2016, as a result of the delay in filing its Form 10-Q for the period ended 31 March 2016.

However, the notice of default did not result in the acceleration of its debt or that of any of its subsidiaries.

Under the indentures on its senior notes, Valeant would receive an additional 60 days from the receipt of the notice to file its 10-Q, failing which it would technically default.

Previously, on 9 May 2016, Valeant had announced that it expected to file the 10-Q 2016 report with the Securities and Exchange Commission and the Canadian Securities Regulators on or before June 10, 2016, which would be well in advance of the 60-day cure date.

Source: PRNewswire

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s